Objective: To delineate the frequency and clinicopathological features of urinary bladder cancer.
Methods: This retrospective study was conducted at the King Fahd Hospital, Madinah, Saudi Arabia, and comprised medical records related to bladder tumours, from January 2006 to October 2015. Data was obtained from histopathologic reports and evaluated for age, gender, cystoscopic findings and histopathological characteristics at the time of presentation.
Results: Of the 116 cases, 96(82.7%) were of men while 20(17.3%) were of women. The mean age was 62.4±15.62 years (range: 20-115 years). Transitional cell carcinoma was the most common histological type, seen in 111(95.7%) cases, followed by adenocarcinoma 3(2.6%) and squamous cell carcinoma 2(1.7%). Of the transitional cell carcinoma cases, 78(70.5%) were superficial, while 33(29.5%) were muscle invasive. Most of the transitional cell carcinoma cases 72(65%) were of lower grade (grade I and II), while 39(35%) were of grade III.
Conclusions: Our hospital-based pathology experience of urinary bladder cancer was comparable with earlier studies.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
KRAS inhibitors: resistance drivers and combinatorial strategies.
Trends Cancer
December 2024
Charité - Universitätsmedizin Berlin, Institute of Pathology, Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address:
In 1982, the RAS genes HRAS and KRAS were discovered as the first human cancer genes, with KRAS later identified as one of the most frequently mutated oncogenes. Yet, it took nearly 40 years to develop clinically effective inhibitors for RAS-mutant cancers. The discovery in 2013 by Shokat and colleagues of a druggable pocket in KRAS paved the way to FDA approval of the first covalently binding KRAS inhibitors, sotorasib and adagrasib, in 2021 and 2022, respectively.
View Article and Find Full Text PDFEfficacy of corneal squamous cell carcinoma antigen-1 in early infancy in predicting atopic dermatitis and food allergy: A prospective study.
Allergol Int
December 2024
Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Background: Identification of predictive biomarkers is crucial for formulating preventive interventions and halting the progression of atopic march. Although controversial, the use of accessible markers to predict or detect early onset of atopic diseases is highly desirable. Therefore, this study aimed to investigate whether corneal squamous cell carcinoma antigen-1 (SCCA1) collected from infants can predict the development of atopic dermatitis and food allergy.
View Article and Find Full Text PDFCorrigendum to "Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma" [Cancer Lett. 604 (2024) 217272].
Cancer Lett
December 2024
Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong; Peter Hung Pain Research Institute, The Chinese University of Hong Kong, Hong Kong. Electronic address:
Prognostic impact of tumor cell nuclear size assessed by artificial intelligence in esophageal squamous cell carcinoma.
Lab Invest
December 2024
Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan.
Tumor cell nuclear size (NS) indicates malignant potential in breast cancer; however, its clinical significance in esophageal squamous cell carcinoma (ESCC) is unknown. Artificial intelligence (AI) can quantitatively evaluate histopathological findings. The aim was to measure NS in ESCC using AI and elucidate its clinical significance.
View Article and Find Full Text PDFDifferential gene expression in PBMCs: Insights into the mechanism how pulmonary tuberculosis increases lung cancer risk.
Gene
December 2024
Scientific Research Center, The Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, China; Department of Clinical Laboratory, The Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, China. Electronic address:
Pre-existing of pulmonary tuberculosis (PTB) poses increased lung cancer risk, yet the molecular mechanisms remain inadequately understood. This study sought to elucidate the potential mechanisms by performing comprehensive analyses of differentially expressed genes (DEGs) in peripheral blood mononuclear cells (PBMCs) from patients with PTB, lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC). Microarray assays were employed to analyze the DEGs in PBMCs of these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!